Different stages of intoxication correlate with increasing BAC levels, with more severe symptoms appearing as BAC approaches 0.08% and beyond
Progress monitoring at weeks 4, 8, and 12 with protocol adjustment
Head-to-head comparisons are limited, but existing data suggests GHK-Cu produces broader systemic effects while AHK-Cu may offer advantages in localized dermal applications
Faucher K, Rabinovitch-Chable H, Cook-Moreau J, Barriere G, Sturtz F, Rigaud M
Week 1: 50mcg nightly Week 2: 100mcg nightly (if Week 1 tolerated well) Weeks 3-4: 150mcg nightly (if no adverse effects) Weeks 5-8: 200-300mcg nightly (target maintenance dose) Gradual titration helps identify your minimum effective dose while avoiding unnecessary exposure to higher amounts